The prevention of transplant rejection in renal safety profile MMF in a daily dose of 2 g was slightly winstrol for women better than a daily dose of 3 g
Postmarketing use of the drug Ingestion: colitis (sometimes etiology cytomegalovirus), pancreatitis, isolated cases of intestinal villous atrophy. Immune System: isolated cases of severe, life-threatening infections (meningitis, infectious endocarditis), increase in the frequency of some infections such as tuberculosis and atypical mycobacterial infections.
Overdose of mycophenolate mofetil in humans Data not.
IFC can not be removed from the body by hemodialysis. However, at high concentrations in plasma (> 100 ug / ml), small amounts of it still displayed. Formulations binding bile acids, such as cholestyramine, can help eliminate from the body, increasing its excretion.
Drug interactions Acyclovir. With simultaneous use winstrol for women and acyclovir increases the concentration of both drugs in plasma of renal failure, perhaps as a result of competition in relation to tubular secretion, which can result in further increasing concentrations of both drugs. Antacids containing magnesium hydroxide and aluminum reduce the absorption mycophenolate mofetil. cholestyramine: following the appointment of a single dose of 1.5 g of mycophenolate mofetil in healthy volunteers, previously accepted by cholestyramine 4 g 3 times a day for 4 days, there was a decrease .
Caution should be exercised with concomitant administration and drugs that affect the liver-intestinal recycling. Cyclosporine: mycophenolate mofetil did not affect the pharmacokinetics of cyclosporine.Ganciclovir: based on the results of research with a one-time oral administration of the recommended dose of mycophenolate mofetil and intravenous ganciclovir, a significant change in the IFC pharmacokinetics not expected therefore to adjust the dose of mycophenolate mofetil is not necessary. If mycophenolate mofetil and ganciclovir is administered to patients with renal failure, it is necessary to closely monitor patients. Oral contraceptives: does not affect the pharmacokinetics of oral contraceptives to suppress ovulation, under the influence of oral contraceptives. Trimethoprim / sulfamethoxazole: no effect on the bioavailability .
In appointing the drug to pregnant female rats and rabbits during organogenesis observed winstrol for women adverse effects on the fetus (including malformations); These effects are developed using doses, no toxic effects on mother and lower doses recommended for clinical use after transplantation of kidney, heart or liver. There are no adequate and well-controlled studies in pregnant women have been conducted. However, since the drug has teratogenic effects in animals, it can adversely affect the fetus and the person. MMF may be administered to pregnant women only if the potential benefit to the mother outweighs the potential risk to the fetus.
MMF should not begin until then, until a negative result is screening for pregnancy when using the method of serum or urine test with a sensitivity of at least 50 mIU / ml. Prior to initiating therapy with MMF, during treatment and for 6 weeks after the end necessarily use effective methods of contraception, even if a woman has a history of infertility there (except for transferred hysterectomy). If abstinence from sexual activity is not possible, two reliable methods of contraception must be used simultaneously. In the event of pregnancy during therapy should discuss the desirability of maintaining it with the doctor.
In rats, mycophenolate mofetil is excreted in the milk. Do winstrol for women with human milk is unknown Provided. As with breast milk excreted many drugs, as well as due to the possibility of serious adverse reactions to mycophenolate mofetil in infants, the choice between continuing breastfeeding or taking this medication do considering the importance of the treatment to the mother.